2Vitale A, Sota J, Rigante D, et al. Relapsing polychondritis: an update on pathogenesis, clinical features, diagnostic tools, and therapeutic perspectives[J]. Cma" Rheumatol Rep, 2016, 18(1 ): 3-6. DOI: 10.1007/s11926-015-0549-5.
3Lin DF, Yang WQ, Zhang PP, et al. Clinical and prognostic characteristics of 158 cases of relapsing polychondritis in China and review of the literature[J]. Rheumatol Int, 2016, 36 (3) : 7- 11. DOI: 10.1007/s00296-016-344%8.
4Sharma A, Law AD, Bambery P, et al. Relapsing polychon- dfitis: clinical presentations, disease activity and outcomes[J].Orphanet J Rare Dis, 2014, 9(12): 198-204. DOI: 10.1186/ s13023-014-0198-1.
5McAdam LP, O' Hanlan MA, Bluestone R, et al. Relapsing polychondritis: prospective study of 23 patients and a review of the literature[J]. Medicine, 1976, 55(3): 193-215.
6Hazra N, Dregan A, Charhon J, et al. Incidence and mortality of relapsing polyehondritis in the UK: a population-based cohort study [J]. Rheumatology (Oxford), 2015, 54 ( 12 ): 218 i-2187. DOI: 10.1093/rheumatology/kev240.
7Cantarini L, Vitale A, Brizi MG, et al. Diagnosis and elas- i sification of relapsing polychondritis[J]. J Autoimmun, 2014, 13(2): 53-59. DOI: 10.1016/j.jant.2014.01.026.
8Arnaud L, Mathian A, Haroche J, et al. Pathogenesis of relapsing polychondritis: a 2013 update[J]. Autoimmun Rev, 2014, 13(2): 90-95. DOI: 10.1016/j.autrev.2013.07.005.
10Pasquet F, Pavic M, Ninet J, et al. Auto-immune diseases and cancers. Second part: auto-immune diseases complicating cancers and their treatment[J]. Rev Med Interne, 2014, 35(10): 656- 663. DOI: 10.1016/j.revmed.2014.04.004.
